Faculty Opinions recommendation of Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Year: 2020
Type: peer-review
Authors: Jun J Yang, Heng Xu
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funders: National Science Foundation, Conquer Cancer Foundation, Breast Cancer Research Foundation, V Foundation for Cancer Research, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, American Society of Clinical Oncology, Memorial Sloan-Kettering Cancer Center, Varian Medical Systems, Society of Memorial Sloan Kettering, Foghorn Therapeutics, Agios Pharmaceuticals, Revolution Medicines, Puma Biotechnology, G1 Therapeutics, National Institutes of Health, Genentech, Stand Up To Cancer, National Cancer Institute
Awards: G1229558712, G1766785608, G2051006376, Mechanisms of action of dual compound oncogenic PIK3CA mutations, G289723095, G3520485882, G4583515593, Unraveling resistance to PI3K-alpha inhibitors in breast cancer, G5944639382, G6516949535, G7556015768, G782458776, G9000003249, Cancer Center Support Grant, Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism
OpenAlex ID: W4232527416